Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Understanding Kaposi Sarcoma and Its Subtypes

At a Glance

Kaposi sarcoma (KS) is a manageable cancer of the blood or lymph vessels caused by the HHV-8 virus. Treatment depends on which of the five subtypes you have, but often focuses on strengthening the immune system to help shrink skin lesions and control the disease.

Kaposi sarcoma (KS) is a type of cancer that develops from the cells that line lymph or blood vessels [1]. It typically appears as purple, red, or brown blotches or tumors on the skin, but it can also affect the mouth or internal organs [2][3]. While a cancer diagnosis is always serious, it is important to know that KS is highly treatable and often manageable as a chronic condition [4][5].

The Cause: HHV-8

All forms of Kaposi sarcoma are caused by a virus called Human Herpesvirus 8 (HHV-8), also known as Kaposi Sarcoma-associated Herpesvirus (KSHV) [1][6]. While many people carry this virus without ever getting sick, KS can develop if the immune system is weakened or if there are other specific risk factors [7][8].

Three Stabilizing Facts

If you have just been diagnosed, keep these three points in mind to help ground your perspective:

  1. Highly Manageable: Most forms of KS are treatable and often progress very slowly (indolent). For many, the primary goal is symptom control rather than aggressive intervention [9][10].
  2. Immune Control is Key: In many cases, especially those related to HIV, simply strengthening or adjusting the immune system (such as through Antiretroviral Therapy or ART) can cause the lesions to shrink or disappear without traditional chemotherapy [4][11].
  3. Modern Treatments are Effective: We have a wide range of options today, from local therapies like radiation for small areas to highly effective systemic drugs like liposomal doxorubicin or paclitaxel for more advanced cases [12][13].

The Five Subtypes of Kaposi Sarcoma

Doctors classify KS into five distinct subtypes based on who is affected and why the disease developed. Understanding your subtype helps your care team determine the best management strategy [1][9].

1. Epidemic (AIDS-Related) KS

This is the most common subtype in the United States and occurs in people living with HIV [14].

  • Demographics: Typically affects younger adults (ages 20–50); much more common in men than women [14][7].
  • Behavior: It can range from a few skin spots to widespread involvement of the lungs, liver, or digestive tract. The cornerstone of treatment is ART to suppress the HIV virus and boost the immune system [4][15].

2. Classic KS

This version usually affects older adults and follows a very slow, long-term course [7][1].

  • Demographics: Primarily affects men (the ratio can be as high as 10:1 or 15:1) over the age of 60 who are of Mediterranean, Middle Eastern, or Eastern European descent [1][7].
  • Behavior: Lesions usually appear on the lower legs or feet and grow very slowly over many years [1][3].

3. Endemic (African) KS

This subtype occurs in people living in equatorial Africa, where HHV-8 is very common in the general population [16].

  • Demographics: It affects two main groups: adults (mostly men) and children [17][16].
  • Behavior: In adults, it often behaves like Classic KS. In children, it can be much more aggressive, involving the lymph nodes and internal organs [17][16].

4. Iatrogenic (Transplant-Related) KS

This form develops in people whose immune systems are being suppressed by medications, usually after an organ transplant to prevent rejection [18][19].

  • Demographics: Occurs in 0.5% to 5% of transplant recipients; most commonly seen in middle-aged adults [18][19].
  • Behavior: Management often involves carefully reducing or changing the immunosuppressive medications to allow the patient’s own immune system to fight the KS [18][19].

5. Non-Epidemic KS

This is an emerging category found in individuals who are HIV-negative and have no other known immune system problems [10][20].

  • Demographics: Primarily seen in HIV-negative men who have sex with men (MSM), typically under the age of 60 [3][20].
  • Behavior: It behaves very similarly to Classic KS, usually staying on the skin and progressing very slowly with a favorable long-term outlook [10][21].
Subtype Primary Population Typical Behavior
Epidemic People living with HIV Ranges from indolent to aggressive; responds well to ART [4][15]
Classic Elderly Mediterranean/European men Very slow-growing; usually limited to lower legs [1][7]
Endemic People in sub-Saharan Africa Can be slow (adults) or very aggressive (children) [17][16]
Iatrogenic Transplant recipients Linked to immune-suppressing drugs; can improve if drugs are adjusted [18]
Non-Epidemic HIV-negative MSM Similar to Classic KS; slow-growing with a good prognosis [10][21]

Common questions in this guide

What causes Kaposi sarcoma?
All forms of Kaposi sarcoma are caused by the Human Herpesvirus 8, also known as HHV-8 or KSHV. The virus can lead to cancer when a person's immune system is weakened by other medical conditions or immune-suppressing medications.
Can Kaposi sarcoma be cured?
While Kaposi sarcoma is often managed as a chronic condition rather than being completely cured, modern treatments are highly effective. For many patients, strengthening the immune system is enough to make the lesions shrink or disappear.
How does HIV status affect Kaposi sarcoma?
Epidemic Kaposi sarcoma is the most common subtype in the United States and occurs in people living with HIV. By using antiretroviral therapy (ART) to treat the HIV and boost the immune system, doctors can often successfully control the Kaposi sarcoma.
Will I need traditional chemotherapy for Kaposi sarcoma?
Not necessarily. Many early or slow-growing cases are treated by adjusting medications to improve immune function. However, if the cancer is more advanced, highly effective systemic medications like liposomal doxorubicin or paclitaxel are available.
What are the symptoms of Kaposi sarcoma besides skin spots?
In addition to purple, red, or brown skin lesions, Kaposi sarcoma can sometimes affect internal organs or lymph nodes. This internal involvement might cause symptoms like unexplained swelling in your legs, shortness of breath, or stomach pain.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific subtype of Kaposi Sarcoma do I have, and how was that determined?
  2. 2.Is my KS related to my immune system's current state, such as HIV status or medications I'm taking?
  3. 3.Have you checked for any internal involvement (visceral disease) beyond the skin lesions?
  4. 4.Based on my subtype, is the goal of treatment to cure the disease or to manage it as a chronic condition?
  5. 5.What are the most appropriate treatment options for my specific subtype and the extent of my lesions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Prognostic factors in Kaposi sarcoma, single centre experience.

    Değerli E, Oruç K, Şentürk Öztaş N, et al.

    The Australasian journal of dermatology 2024; (65(5)):444-450 doi:10.1111/ajd.14309.

    PMID: 38760927
  2. 2

    Kaposi's sarcoma immune reconstitution inflammatory syndrome: A forgotten entity nowadays.

    Cristina FR, Lorena VC, Tamara FS, et al.

    Indian journal of sexually transmitted diseases and AIDS 2024; (45(2)):151-154 doi:10.4103/ijstd.ijstd_57_24.

    PMID: 39886246
  3. 3

    Kaposi Sarcoma: Retrospective Clinical Analysis with a Focus on Age and HIV Serostatus.

    Erçin Z, Toprak M

    Viruses 2026; (18(1)) doi:10.3390/v18010144.

    PMID: 41600905
  4. 4

    A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.

    Ramaswami R, Uldrick TS, Polizzotto MN, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(14)):4238-4247 doi:10.1158/1078-0432.CCR-18-3528.

    PMID: 30979736
  5. 5

    Update on oncogenesis and therapy for Kaposi sarcoma.

    Dupin N

    Current opinion in oncology 2020; (32(2)):122-128 doi:10.1097/CCO.0000000000000601.

    PMID: 31815777
  6. 6

    Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis.

    Schulz TF, Cesarman E

    Current opinion in virology 2015; (14()):116-28.

    PMID: 26431609
  7. 7

    A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris.

    Denis D, Seta V, Regnier-Rosencher E, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(8)):1377-1384 doi:10.1111/jdv.14831.

    PMID: 29377280
  8. 8

    A case of mistaken identity: classic Kaposi sarcoma misdiagnosed as a diabetic foot ulcer in an atypical patient.

    Torrence GM, Wrobel JS

    Clinical diabetes and endocrinology 2019; (5()):8 doi:10.1186/s40842-019-0083-x.

    PMID: 31333876
  9. 9

    An unusual series of patients with Kaposi sarcoma.

    Wang J, Reid H, Klimas N, Koshelev M

    JAAD case reports 2019; (5(8)):646-649 doi:10.1016/j.jdcr.2019.05.016.

    PMID: 31388528
  10. 10

    Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022.

    Morales AE, Benson G, Glavan S, et al.

    The oncologist 2025; (30(3)) doi:10.1093/oncolo/oyaf024.

    PMID: 40079529
  11. 11

    Evolution of Kaposi sarcoma in the past 30 years in a tertiary hospital of the European Mediterranean basin.

    Marcoval J, Bonfill-Ortí M, Martínez-Molina L, et al.

    Clinical and experimental dermatology 2019; (44(1)):32-39 doi:10.1111/ced.13605.

    PMID: 29934954
  12. 12

    Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.

    Chapola JC, Kleber SL, Krown SE, Painschab M

    Cost effectiveness and resource allocation : C/E 2025; (23(1)):78 doi:10.1186/s12962-025-00677-x.

    PMID: 41286911
  13. 13

    AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

    Reid E, Suneja G, Ambinder RF, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2019; (17(2)):171-189.

    PMID: 30787130
  14. 14

    Primary penile Kaposi's sarcoma in HIV-seronegative patient: a case report and literature review.

    Cito G, Di Costanzo R, Morselli S, et al.

    International braz j urol : official journal of the Brazilian Society of Urology 2020; (46(5)):825-842 doi:10.1590/S1677-5538.IBJU.2020.05.03.

    PMID: 32648423
  15. 15

    Gastric Ulcer as Presentation of HIV-Associated Kaposi Sarcoma and Resolution With HAART Therapy.

    Nassri R, Muftah A, Muftah M, et al.

    ACG case reports journal 2019; (6(10)):e00262 doi:10.14309/crj.0000000000000262.

    PMID: 31832479
  16. 16

    Kaposi Sarcoma Updates.

    Etemad SA, Dewan AK

    Dermatologic clinics 2019; (37(4)):505-517 doi:10.1016/j.det.2019.05.008.

    PMID: 31466590
  17. 17

    Endemic Kaposi's Sarcoma.

    Zeinaty PE, Lebbé C, Delyon J

    Cancers 2023; (15(3)) doi:10.3390/cancers15030872.

    PMID: 36765830
  18. 18

    Kaposi's Sarcoma. A Case Report.

    Polách O, Kopecký A, Wandrolová Z, et al.

    Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 2024; (80(2)):114-118 doi:10.31348/2024/16.

    PMID: 38531684
  19. 19

    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.

    Delyon J, Rabate C, Euvrard S, et al.

    Journal of the American Academy of Dermatology 2019; (81(2)):448-455 doi:10.1016/j.jaad.2019.03.028.

    PMID: 30902727
  20. 20

    A description of Kaposi sarcoma risk factors and outcomes in HIV-positive and HIV-negative patients at a tertiary care medical center from 2005 to 2020.

    Libson K, Himed S, Dunlop H, et al.

    Archives of dermatological research 2023; (315(7)):2159-2162 doi:10.1007/s00403-023-02552-2.

    PMID: 36856854
  21. 21

    [A new form of Kaposi sarcoma].

    Derickx LAJ, Houwing RH, van Bergen BH, et al.

    Nederlands tijdschrift voor geneeskunde 2021; (165()).

    PMID: 34523837

This page provides educational information about Kaposi sarcoma and its subtypes. Always consult your oncologist or infectious disease specialist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Kaposi sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.